Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
276. |
ECCT/15/11/04 | VAC040 A Phase 1/2, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety, Tolerability, and Immunogenicity of Stretococcus pneumoniae Whole Cell Vaccine,… read more |
Principal Investigator(s) 1. John Anthony Gerard Scott Site(s) in Kenya KEMRI-Wellcome Trust Research Program |
View |
277. |
ECCT/18/12/01 | study to determine if a new malaria vaccine is safe and induces immunity among Kenyan adults, young children and infants. A Phase 1b, open-label, age de-escalation, dose-escalation… read more |
Principal Investigator(s) 1. Mainga Hamaluba Site(s) in Kenya KEMRI-Wellcome Trust Research Programme (KWTRP) Centre for Geographic Medical Research - Coast (… read more |
View |
278. |
ECCT/24/03/01 |
RAD-TB A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis |
Principal Investigator(s) 1. Dr Josphat Kosgei Kosgei Site(s) in Kenya Kenya medical research institute/ Walter Reed program KERICHO |
View |
279. |
ECCT/24/02/02 | Sabin 003 A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-… read more |
Principal Investigator(s) 1. Prof. Videlis Nduba Nzioka Site(s) in Kenya KEMRI / CRDR, KEMRI Clinical Research Annex, Siaya County Referral Hospital Ground.… read more |
View |
280. |
ECCT/22/07/01 | GBT021601-021 Study A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in… read more |
Principal Investigator(s) 1. Jessie Nyokabi Githanga 2. Berhnards Ragama Ogutu 3. Videlis Nduba 4. Berhnards Ragama Ogutu Site(s) in Kenya… read more |
View |